CE-VST01-JC ( DrugBank: CE-VST01-JC )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 25 | Progressive multifocal leukoencephalopathy | 1 |
25. Progressive multifocal leukoencephalopathy
Clinical trials : 26 / Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05541549 (ClinicalTrials.gov) | February 2023 | 13/9/2022 | A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML | ASCEND-JC: A Multi-center, Randomized, Double-blind, Phase 2 Study, Evaluating JCPyV-specific T Cell Therapy for the Treatment of PML | Progressive Multifocal Leukoencephalopathy | Biological: CE-VST01-JC | Cellevolve Bio Inc | NULL | Not yet recruiting | 18 Years | N/A | All | 60 | Phase 2 | NULL |